Monday morning kicks off one of the largest biotech events of the year: the JP Morgan Healthcare Conference. This conference is a four day event of the “who’s who” in the world of biotech. Here, companies large and small will present their 2019 milestones achieved, and pitch their aspirations for 2020 and beyond to investors and larger pharma companies. Often, companies will pre-announce sales for the year/quarter ended December 31st, 2019. This also provides a great venue to announce and tout new collaborations, or in the case of LOXO Oncology and Eli Lilly, announce a new blockbuster merger. So what are we watching this year? Well here our team briefly outlines two companies that we are each intrigued by and why.
Chris (CPO): This year at JPM20 I am closely watching TG Therapeutics (TGTX) and Nantkwest (NK). TG Therapeutics has been covered by us previously, and recently secured additional funding, which helps their balance sheet. They have a packed 2020 planned with several key pivotal trial readouts and a planned NDA filing. This year has the making for a pivotal time in TG Therapeutic’s history. On a smaller front, Nantkwest seeks to harness the innate immune system by uses off-the shelf Natural Killer cells. In late 2019, they announced positive data at the San Antonio Breast Cancer Symposium for patients with late line triple-negative breast cancer. I am very curious to see how they outline their priorities for 2020 and what expectations they set for the year.
For those interested, the full conference agenda is placed below:
This is not a recommendation to buy/sell securities.
I/we long TGTX.
MS Money Move and its Chief Operating Officer who is a scientist and individual investor, as well as its affiliates are not registered financial advisors. Our posts should serve as educational material to help you conduct due diligence research. Posts and articles are not directives or recommendations to invest in any security. We reserve the right to buy or sell any security for ourselves without any notification except when required by law. We are not responsible for the action of our affiliates. Investment theses may change due to the variable nature of the securities market. Because of this there is great risk when investing in stocks and options which can result is capital loss. Additionally, past performance by MS Money Moves or any security is not a predictor of future performance. Everyone should conduct their own research and due diligence before making an investment decision. We recommend you consult a financial advisor regarding any investment action.
The biotech sector is especially volatile. Stock prices may fluctuate substantially based on material or nonmaterial developments. We encourage everyone to familiarize themselves with clinical trial processes, relevant terminology, FDA/SEC rules and regulations, and the general processes of drug & therapy development/approval. Always do independent research in a security prior to investing.